ADVERTISEMENT
Abstract
ARRY-520 has promising single-agent activity in heavily pretreated patients who have progressed after multiple therapies
ADVERTISEMENT
Related articles
Poster
non-peer-reviewed
A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma
Not Selected
Array BioPharmaAuthor Information
Array BioPharma Corresponding Author
Not Selected
Poster Information
Publication history
Published: September 17, 2012
Copyright
© Copyright 2012
BioPharma. This is an open access poster distributed under the terms of the Creative Commons Attribution License CC-BY 3.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License
This is an open access poster distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.